title: Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
authors.affiliation: Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.forename: Antonio
authors.initials: A
authors.lastname: Palermo
authors.forename: Antonello
authors.initials: A
authors.lastname: Veccia
authors.forename: Francesca
authors.initials: F
authors.lastname: Maines
authors.forename: Franca
authors.initials: F
authors.lastname: Chierichetti
authors.forename: Enzo
authors.initials: E
authors.lastname: Galligioni
mesh_terms: D000069501:Abiraterone Acetate; D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D013375:Substance Withdrawal Syndrome / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
chemical_list: D000730:Androstadienes; D013254:Steroid 17-alpha-Hydroxylase; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate
keywords: Abiraterone; Castration resistant prostate cancer; Choline positron emission tomography; Withdrawal response